Diagnosis

NASH/NAFLD requires a positive diagnosis to be made, these videos explain more on how this disease can be diagnosed.

All Comorbidities Definition Diagnosis Epidemiology Management Nash Treatment Pathophysiology PPAR Agonists

Cancers and NASH

Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.

View More ⏩

Link between NAFLD and HFpEF

Dr. Marat Fudim (USA) reviews the interaction between NAFLD and Heart Failure with preserved Ejection Fraction (HFpEF), including highlights of the global prevalence rate of NAFLD.

View More ⏩

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm

View More ⏩

Biomarkers in NASH

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.

View More ⏩

Prof. Pierre Rautou
November 26, 2020
Diagnosis

Microvesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. Rautou

Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He discusses what we know about microvesicles in NASH and the rationale to consider them as biomarkers in liver disease.

View More ⏩